GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC), a
biopharmaceutical company developing gene-based medicines, today announced
that Chief Executive Officer, Dr. Paul H. Fischer, will present a corporate
overview and clinical development updates on its product candidates at the JP
Morgan H&Q 20th Annual Healthcare Conference in San Francisco, California on
Thursday, January 10th, 2002 at 10:30 am Pacific Time (1:30 pm Eastern).
The presentation will be web cast and may be accessed live through
GenVec's web site at http://www.genvec.com . Please log-on to the presentation
web cast before it begins to allow for processing and any downloads that may
be required to participate. An archived version of the presentation will also
be available on the Company's web site for several days after the conference.
GenVec is a publicly held biotechnology company focused on the development
and commercialization of novel gene-based therapies that produce medically
beneficial proteins at the site of disease. The company combines its patented
gene transfer technologies with proprietary therapeutic genes to create
product candidates, including BIOBYPASS (R) angiogen for cardiovascular
disease, TNFerade(TM) for oncology and AdPEDF for ophthalmology. Additional
information on GenVec is available at its web site located at
http://www.genvec.com and in the company's various filings with the Securities
and Exchange Commission.
Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding future revenues and operating expenses, are forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act. Forward-looking statements are typically identified by words or
phrases such as "believe," "expect," "anticipate," "intend," "estimate,"
"assume," "plan," "outlook," "prospect," and variations of such words and
similar expressions, or future or conditional verbs such as "will," "would,"
"should," "could," "may," or similar expressions. GenVec cautions that these
forward-looking statements are subject to numerous assumptions, risks and
uncertainties, which change over time. The following factors, among others,
could cause actual results to differ materially from forward-looking
statements or historical experience: risks relating to the early stage of
product candidates under development, risks relating to GenVec's ability to
identify and enter into agreements with potential collaborative partners,
uncertainties relating to clinical trials, dependence on third parties, future
capital needs, and risks relating to the commercialization, if any, of
GenVec's proposed product candidates (such as marketing, regulatory, patent,
product liability, supply, competition and other risks). GenVec's SEC reports
identify additional factors that can affect forward-looking statements. These
forward-looking statements speak only as of the date of this press release,
and GenVec assumes no duty to update forward-looking statements.
SOURCE GenVec, Inc.
 back to top
Related links:
http://www.genvec.com
CONTACT:
Mary P. Sundeen, Executive Director, Corp.
Communications of GenVec, Inc., +1-240-632-5533 or
+1-240-372-7194 or msundeen@genvec.com
|
